News | December 14, 2022
Balaxi conducts groundbreaking for its Rs 85 crore Hyderabad manufacturing facility
The investment will enable the company to enter European markets as well as enhance margins in current markets
The investment will enable the company to enter European markets as well as enhance margins in current markets
The company currently supplies one product to the US market that contributes low- single digit revenue to Jubilant Pharmova revenue
Sud has more than 32 years of work experience with different companies like Clivient, Jubilant Life Sciences, Piramal Enterprises, Parabolic Drugs, Orchid Chemicals and Pharmaceuticals, Ranbaxy Labs, and Lupin
_256_384.jpg){kind=logo}
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
Proceeds from the proposed issue will be utilized to part finance Balaxi’s planned EU GMP-compliant manufacturing facility for Oral Solid Dosages and Liquid Injectables at TSIIC Pharma Formulations SEZ
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
The Board also decided that Auro Vaccines will explore the possibilities of offering contract manufacturing to global vaccine developers
The company is relieving all its staff who were directly engaged by our US subsidiary in its plant in connection with the manufacturing process in a phased manner
The appointments will add to the well-diversified experience that currently exists on the PPL board.
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
Subscribe To Our Newsletter & Stay Updated
